Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cell & Gene Therapy

Stem cell research and commercialization in China...

Nanjing's NJCTTQ Signs $4 Billion In-Licensing Deal for Bi-Specific Immunotherapies from Abpro

Innovent Combines PD-1 with Avastin Biosimilar in China HCC Trial

Gracell Biotech of Suzhou Completes $85 Million Series B for Immune Cell Gene Therapies

WuXi NextCODE Participates in $68 Million DNAnexus Funding

EdiGene Completes $10 Million Round for Gene Editing-based Discovery

Upcoming event
Shanghai , China
May 8-9, 2019
Take advanage of the early bird discount before March 31, 2019.
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Shanghai , China
March 26-28, 2019